Nano X Imaging Ltd. has made significant strides in expanding its U.S. commercial presence with a new distribution agreement between its subsidiary, Nanox Impact Inc., and Digital X-Ray Imaging Inc. This partnership aims to enhance the deployment of the Nanox.ARC, an FDA-cleared digital tomosynthesis system that facilitates 3D imaging at a lower cost and with reduced radiation exposure compared to traditional CT systems. The agreement will enable DXI to market and support the Nanox.ARC across its extensive network of healthcare facilities in Arkansas, leveraging its established relationships and service capabilities.

The significance of this collaboration lies in its potential to transform diagnostic imaging practices. The Nanox.ARC offers a practical alternative for healthcare providers seeking access to advanced 3D imaging without the financial and infrastructural burdens associated with conventional CT systems. According to Drew Baxter, President of DXI, there is a notable demand for the Nanox.ARC among their customer base, indicating a market readiness for more cost-effective imaging solutions that do not compromise clinical efficacy. This aligns with Nanox’s vision of making preventive healthcare more accessible through innovative imaging technologies.

The key takeaway from this development is the acceleration of digital tomosynthesis adoption as a primary imaging option, which could reshape current research paradigms in imaging technology and diagnostics. By integrating the Nanox.ARC into existing healthcare workflows, this partnership not only streamlines the sales cycle but also enhances clinical evaluations, paving the way for broader implementation of advanced imaging solutions. This shift may influence future drug development timelines by facilitating earlier disease detection and improving patient outcomes, ultimately advancing the field of longevity science.

Source: globenewswire.com